These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 32737681)
1. Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach. Kanhed AM; Patel DV; Teli DM; Patel NR; Chhabria MT; Yadav MR Mol Divers; 2021 Feb; 25(1):383-401. PubMed ID: 32737681 [TBL] [Abstract][Full Text] [Related]
2. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760 [TBL] [Abstract][Full Text] [Related]
3. An automated positive selection screen in yeast provides support for boron-containing compounds as inhibitors of SARS-CoV-2 main protease. Sigurdardóttir S; Silva SF; Tiukova I; Alalam H; King RD; Grøtli M; Eriksson LA; Sunnerhagen P Microbiol Spectr; 2024 Oct; 12(10):e0124924. PubMed ID: 39162260 [TBL] [Abstract][Full Text] [Related]
4. Ensemble docking based virtual screening of SARS-CoV-2 main protease inhibitors. Fomina AD; Uvarova VI; Kozlovskaya LI; Palyulin VA; Osolodkin DI; Ishmukhametov AA Mol Inform; 2024 Aug; 43(8):e202300279. PubMed ID: 38973780 [TBL] [Abstract][Full Text] [Related]
5. Biochemical screening for SARS-CoV-2 main protease inhibitors. Coelho C; Gallo G; Campos CB; Hardy L; Würtele M PLoS One; 2020; 15(10):e0240079. PubMed ID: 33022015 [TBL] [Abstract][Full Text] [Related]
6. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors. Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303 [TBL] [Abstract][Full Text] [Related]
7. Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking Studies Unveil an Opportunity Against CORONA. Arif MN Comb Chem High Throughput Screen; 2022; 25(1):197-203. PubMed ID: 33231155 [TBL] [Abstract][Full Text] [Related]
8. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study. Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867 [TBL] [Abstract][Full Text] [Related]
9. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862 [TBL] [Abstract][Full Text] [Related]
10. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity. Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763 [TBL] [Abstract][Full Text] [Related]
11. COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor. Feitosa EL; Júnior FTDSS; Nery Neto JAO; Matos LFL; Moura MHS; Rosales TO; De Freitas GBL Int J Med Sci; 2020; 17(14):2133-2146. PubMed ID: 32922174 [TBL] [Abstract][Full Text] [Related]
12. Discovery of potential inhibitors targeting SARS-CoV-2 Mpro. Zhou WW; Li DS; Chen Y; You BQ; Zheng YF; Li Y; Si SY; Zhang J Eur Rev Med Pharmacol Sci; 2024 Sep; 28(18):4313-4325. PubMed ID: 39359203 [TBL] [Abstract][Full Text] [Related]
14. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Kandeel M; Al-Nazawi M Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634 [TBL] [Abstract][Full Text] [Related]
15. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study. Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389 [TBL] [Abstract][Full Text] [Related]
16. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
17. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19. Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074 [TBL] [Abstract][Full Text] [Related]
18. Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors. Pundir H; Joshi T; Joshi T; Sharma P; Mathpal S; Chandra S; Tamta S Mol Divers; 2021 Aug; 25(3):1731-1744. PubMed ID: 33079314 [TBL] [Abstract][Full Text] [Related]
19. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682 [TBL] [Abstract][Full Text] [Related]
20. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants. Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]